Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.
作者信息
Anand Anil C, Acharya Subrata K
机构信息
Department of Gastroenterology & Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, 751024 Odisha, India.
KIIT University, Bhubaneswar, 751024 Odisha, India.
出版信息
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):263-267. doi: 10.1016/j.jceh.2022.01.008. Epub 2022 Jan 25.
Abstract
摘要
相似文献
1
Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.非酒精性脂肪性肝炎、过氧化物酶体增殖物激活受体与我们优良的格列酮类药物：实践出真知。
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):263-267. doi: 10.1016/j.jceh.2022.01.008. Epub 2022 Jan 25.
2
Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.司美格鲁肽治疗非酒精性脂肪性肝病：91例患者的单中心经验
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):435-439. doi: 10.1016/j.jceh.2021.06.015. Epub 2021 Jun 19.
3
Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.虾青素和安卡黄素作为天然 AMPK 激活剂，具有 PPARα 激动剂活性，可下调高脂饮食喂养的 C57BL/6 小鼠的非酒精性脂肪性肝炎。
Food Chem Toxicol. 2014 Feb;64:94-103. doi: 10.1016/j.fct.2013.11.015. Epub 2013 Nov 22.
4
Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.沙罗格列扎用于合并糖尿病血脂异常的非酒精性脂肪肝患者的安全性和有效性——一项前瞻性、干预性、试点研究
J Clin Exp Hepatol. 2022 Jan-Feb;12(1):61-67. doi: 10.1016/j.jceh.2021.03.012. Epub 2021 Apr 9.
5
Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.胰十二指肠切除术后非酒精性脂肪性肝炎的发生机制
BBA Clin. 2015 Feb 19;3:168-74. doi: 10.1016/j.bbacli.2015.02.001. eCollection 2015 Jun.
6
Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.受控衰减参数在非酒精性脂肪性肝炎纤维化预测中的价值。
World J Gastroenterol. 2019 Sep 7;25(33):4959-4969. doi: 10.3748/wjg.v25.i33.4959.
7
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.过氧化物酶体增殖物激活受体及其激动剂在非酒精性脂肪性肝病中的作用
J Clin Exp Hepatol. 2019 Nov-Dec;9(6):731-739. doi: 10.1016/j.jceh.2019.06.004. Epub 2019 Jul 2.
8
Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.过氧化物酶体增殖物激活受体α和γ2 多态性与非酒精性脂肪性肝病：巴西患者的研究。
Gene. 2013 Oct 25;529(2):326-31. doi: 10.1016/j.gene.2013.06.091. Epub 2013 Jul 24.
9
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.过氧化物酶体增殖物激活受体在非酒精性脂肪性肝病发病机制及治疗中的作用
World J Gastroenterol. 2008 Jan 7;14(1):22-8. doi: 10.3748/wjg.14.22.
10
FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.非酒精性脂肪性肝炎的FibroScan-AST（FAST）评分——在印度队列中的验证
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):440-447. doi: 10.1016/j.jceh.2021.06.008. Epub 2021 Jun 15.
引用本文的文献
1
Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH.用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎的新型组合药物——沙罗格列他与维生素E
J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101449. doi: 10.1016/j.jceh.2024.101449. Epub 2024 May 14.
本文引用的文献
1
Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.司美格鲁肽治疗非酒精性脂肪性肝病：91例患者的单中心经验
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):435-439. doi: 10.1016/j.jceh.2021.06.015. Epub 2021 Jun 19.
2
Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.沙罗格列扎用于合并糖尿病血脂异常的非酒精性脂肪肝患者的安全性和有效性——一项前瞻性、干预性、试点研究
J Clin Exp Hepatol. 2022 Jan-Feb;12(1):61-67. doi: 10.1016/j.jceh.2021.03.012. Epub 2021 Apr 9.
3
Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States.美国制药商向炎症性肠病指南作者支付的未披露款项。
Saudi J Gastroenterol. 2021 Nov-Dec;27(6):342-347. doi: 10.4103/sjg.sjg_426_21.
4
Advancing the global public health agenda for NAFLD: a consensus statement.推进非酒精性脂肪性肝病的全球公共卫生议程：共识声明。
Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27.
5
Genetics Is of the Essence to Face NAFLD.遗传学对于应对非酒精性脂肪性肝病至关重要。
Biomedicines. 2021 Sep 30;9(10):1359. doi: 10.3390/biomedicines9101359.
6
Diet and exercise in NAFLD/NASH: Beyond the obvious.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的饮食和运动：超越显而易见的。
Liver Int. 2021 Oct;41(10):2249-2268. doi: 10.1111/liv.15024. Epub 2021 Aug 21.
7
Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!司美格鲁肽治疗非酒精性脂肪性肝炎：过氧化物酶体增殖物激活受体的故事仍在继续！
Hepatology. 2021 Oct;74(4):1730-1733. doi: 10.1002/hep.32024. Epub 2021 Aug 30.
8
The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD.脂质感应核受体（PPARs 和 LXR）和代谢脂肪酶在肥胖、糖尿病和非酒精性脂肪性肝病中的作用。
Genes (Basel). 2021 Apr 26;12(5):645. doi: 10.3390/genes12050645.
9
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.沙格列汀，一种 PPAR-α/γ 激动剂，用于治疗非酒精性脂肪性肝病：一项随机对照、双盲 2 期试验。
Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.
10
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.非酒精性脂肪性肝病合并糖尿病血脂异常患者应用沙格列汀：一项前瞻性、观察性、真实世界研究。
Sci Rep. 2020 Dec 3;10(1):21117. doi: 10.1038/s41598-020-78342-x.
Zotero 插件